

FY2008 Third Quarter Results

February 5, 2009 Santen Pharmaceutical Co., Ltd.



FY2008 Third Quarter Consolidated Financial Results

Head of Administration Division Satoshi Harada

Performance Overview of FY2008 3Q

(billions of yen)

	FY2007 3Q Actual	FY2008 3Q Actual	Var. %
Net Sales	79.2	77.8	- 1.9%
Operating Income	16.6	11.4	- 31.1%*
Ordinary Income	17.0	12.3	- 27.8%*
Net Income	10.7	7.7	- 28.4%*

*A revision of performance forecast was made as of June 10, 2008, due to an increase of R&D expense of DE-109 (Sirolimus) as an initial upfront payment by 5.3 billion yen for the collaboration and license agreement with MacuSight Inc. as of June 2, 2008.

S Net Sales by Business Segment / Overseas Sales

Sales by Business Segment

(billions of yen)


		FY2008 3Q					
	Dome	estic	Over	seas	Tot	al	
	Actual	Var. %	Actual	Var. %	Actual	Var. %	
Prescription Pharmaceuticals	62.63	- 1.0 %	9.78	- 2.6 %	72.41	- 1.2 %	
Ophthalmics	54.91	- 1.2 %	9.69	- 2.3 %	64.60	- 1.4 %	
Anti-rheumatics	7.49	- 0.2 %	0.06	- 40.7 %	7.56	- 0.8 %	
Others	0.22	19.6 %	0.02	67.7 %	0.24	23.0 %	
OTC Drugs	4.01	- 4.9 %	0.00	- 54.6 %	4.02	- 5.1 %	
Medical Devices	0.41	33.7 %			0.41	28.0 %	
Others	0.37	- 16.4 %	0.58	- 39.1 %	0.95	- 31.9 %	
Total	67.43	- 1.2 %	10.37	- 6.0 %	77.81	- 1.9 %	

Overseas Sales

(billions of yen)

	FY2007 3Q		FY2008 3Q	
	Actual	Actual	Var.	Var. %
Europe	6.31	6.69	0.38	6.1 %
U.S.	1.19	0.60	- 0.59	- 49.1 %
Asia	3.51	3.06	- 0.45	- 12.7 %
Others	0.01	0.00	- 0.01	- 79.5 %
Total	11.02	10.37	- 0.65	- 6.0 %

S FY2008 3Q Net Sales: Variances (vs. FY2007 3Q)



Summary of Changes in Income Statement

(billions of yen)

	FY2007	FY2	800	Major Changes	FY2008
	3Q Actual	3Q Actual	Var.		Outlook
Net Sales	79.2	77.8	- 1.4	(Stated in the previous page)	104.0
Cost of Sales	27.8	27.0	- 0.8	- Change in product mix (-0.6%)	36.3
(% of net sales)	35.1%	34.8%	- 0.3pt	- Impact by NHI drug price change (+0.5%)	34.9 %
SGA Total	34.7	39.2	4.5		52.6
(% of net sales)	43.9%	50.4%	6.5pt	6.5pt	
SGA excluding R&D	25.0	24.1	- 0.9	- Japan: Selling expense decrease (-¥0.3 bn.)	33.2
(% of net sales)	31.6%	31.0%	- 0.6pt	- Europe/U.S.: Selling expense decrease (-¥0.5 bn.)	31.9 %
R&D Expense	9.7	15.1	5.4	- Expense increase in Retina (+¥5.1 bn.)	19.4
(% of net sales)	12.3%	19.4%	7.1pt		18.7 %
Operating Income	16.6	11.4	- 5.2		15.1
(% of net sales)	21.0%	14.8%	- 6.2pt		14.5 %
Non-operating Income or Loss	0.4	0.8	0.4		0.5
Non-operating Income	0.9	1.4	0.5		0.8
Non-operating Expense	0.5	0.6	0.1		0.3
Ordinary Income	17.0	12.3	- 4.7		15.6
Extraordinary Gain or Loss	0.2	0.0	- 0.2		0.0
Extraordinary Gain	0.2	0.0	- 0.2		0.0
Extraordinary Loss	0.0	0.0	0.0		0.0
Net Income before Tax	17.2	12.3	- 4.9		15.6
Income Taxes	6.5	4.6	- 1.9	Tax rate: 37.6% (FY07 3Q), 37.4% (FY08 3Q)	5.8
Net Income	10.7	7.7	- 3.0		9.8

Exchange Rates	FY2007 3Q Actual	FY2008 3Q Actual	
US\$	JPY 117.37	JPY 103.05	
Euro	JPY 162.33	JPY 155.00	(

S Performance by Geographic Segment

Net Sales to External Customers

(billions of yen)

		FY2007	FY20	08 3Q
		3Q Actual	Actual	Var.
Jap	an	71.1	69.8	- 1.3
Eur	ope & U.S.	7.5	7.4	- 0.1
	Europe	6.4	6.8	0.4
	U.S.	1.1	0.6	- 0.5
Oth	ers*	0.5	0.5	±0.0
Tot	al	79.2	77.8	- 1.4

Operating Income

(billions of yen)

		FY2007	FY20	FY2008 3Q		
		3Q Actual	Actual	Var.		
Jap	ban	18.3	13.2	- 5.1		
Eur	rope & U.S.	0.4	0.3	- 0.1		
	Europe	0.0	0.2	0.2		
	U.S.	0.5	0.0	- 0.5		
Oth	ners*	- 0.5	- 0.2	0.3		
Elir	mination	- 1.4	- 1.8	- 0.4		
Tot	al	16.6	11.4	- 5.2		

* "Others" are U.S. Korea and Taiwan. Details of major sales and expenses of "Others" are noted below.

- Sales: Prescription pharmaceuticals in Korea and Taiwan

- Expenses: R&D expenses for medical devices in the U.S.

Note: Sales by geographic region differ from overseas sales (i.e. sales by destination).



(billions of yen)

	As of End-March, 2008		As of I	As of End-December, 2008		
	Actual	% of Total	Actual	% of Total	Var.	
Current Assets	102.7	65.6 %	95.4	64.3 %	- 7.3	
Fixed Assets	53.5	34.2 %	53.0	35.7 %	- 0.5	
Deferred Assets	0.2	0.2 %	-	-	- 0.2	
Total Assets	156.5	100.0 %	148.4	100.0 %	- 8.1	
Current Liabilities	26.5	17.0 %	21.0	14.2 %	- 5.5	
Non-current Liabilities	2.8	1.8 %	3.1	2.1 %	0.3	
Total Liabilities	29.4	18.8 %	24.2	16.3 %	- 5.2	
Total Net Assets	127.1	81.2 %	124.2	83.7 %	- 2.9	
Total Liabilities/Net Assets	156.5	100.0 %	148.4	100.0 %	- 8.1	

Major Changes (billions of yen)

Current Assets: Cash and deposits -2.6, Securities -4.6

Current Liabilities: Other payables +3.2, Current portion of long-term debts -5.0,

Income taxes payable -2.5, Allowance for bonus -1.2

Net Assets: Retained earnings +0.9, Unrealized gains on securities -1.3,

Foreign currency translation adjustments -2.5



(billions of yen)

		FY2008 3Q Actual
Cas	sh and cash equivalents at the beginning of the year	51.6
Net	increase/decrease in cash and cash equivalents	- 8.4
	Cash flows from operating activities	7.2
	Cash flows from investing activities	- 3.2
	Cash flows from financial activities	- 11.7
	Effect of exchange rate changes on cash and cash equivalents	- 0.7
Cas	sh and cash equivalents at the end of the year	43.1

Note: "Cash and cash equivalents" include cash equivalents thus differ from "cash and deposits" in the Balance Sheets.

S Capital Expenditures / Depreciation & Amortization / Lease Expenses

(billions of yen)

	FY2007 3Q	FY20	08 3Q
	Actual	Actual	Var.
Capital Expenditures	2.2	2.4	0.2
Depreciation and Amortization	2.4	2.5	0.1
Lease	0.7	0.7	±0.0

Major Capital Expenditures for FY2008 3Q

- Plant construction in China: ¥0.4 billion
- The 3rd phase of Nara R&D Center construction: ¥1.2 billion



FY2008 Third Quarter Status of Clinical Development

Senior Corporate Officer Head of Research and Development Division Toshiaki Nishihata, Ph.D.

S Major Clinical Pipeline List (Red Letters: Changes from 2Q)

			Global stra Produ		Japan (Asia) Product
Domain	Phase I	Phase II	Phase Ⅲ	NDA Filed	Approved
Glaucoma		DE-104 ROCK inhibitor		DE-085 Tafluprost	
		DE-092 Olmesartan	China	Korea	Japan Europe
Corneal Disease (Dry Eye)	DE-105 Combination of peptides	DE-101 Rivoglitazone		DE-089 Diquafosol sodium	
Retinal Disease	Sirol	109 imus 102 d DDS			
Others Inflammation,		DE-103 PDE4 inhibitor	DE-108 Levofloxacin		
Allergy, RA	DE- Apop indu	tosis			

Status of Major Drug Candidate (DE-085)

• DE-085 Tapros in Japan, Taflotan in Europe (Glaucoma, Ocular hypertension)

	Develo	Remarks			
Region	As of Feb. 5, 2009				
Japan	Launched	Approved	Filed in		
	(December 2008 -)	(October 16, 2008)	July 2006		
Europe	Launched*	Launched	Approved		
	(June 2008 -)	(June 2008 -)	(April 2008 -)		
Asia	Korea: Filed	Korea: Filed	Korea: Filed in		
	China: P3	China: P3	Nov. 2007		
* : Launched in Germany, Denmark, <u>Finland, Sweden</u> (countries underlined were added from 2Q of fiscal 2008)					

U.S. Deciding the possibility of NDA filing after detailed study of its marketability

Status of Major Drug Candidate (DE-089)

• **DE-089** (Corneal and conjunctival epithelial disorders associated with dry eye)

	Development Stage		
Region	As of Feb. 5, 2009	As of Nov. 7, 2008 (Previous announcement)	Remarks
Japan	Filed	Filed	Generic name: Diquafosol sodium
			Filed in May 2008

Status of Major Pipeline - Glaucoma, Ocular hypertension -

• DE-092

Region	Development Stage		_
	As of Feb.5, 2009	As of Nov.7, 2008 (Previous announcement)	Remarks
Japan U.S. Europe	Discontinued	P2 Pilot Study	Generic name: Olmesartan

• DE-090

Region	Development Stage		
	As of Feb.5, 2009	As of Nov.7, 2008 (Previous announcement)	Remarks
Japan	P2	P2	Generic name: Lomerizine HCI

• DE-104

Region	Development Stage		
	As of Feb.5, 2009	As of Nov.7, 2008 (Previous announcement)	Remarks
U.S.	P2	P2	ROCK inhibitor
Japan	P2	P2	

Status of Major Pipeline - Corneal disease -

• **DE-101** (Corneal and conjunctival epithelial disorders associated with dry eye)

	Development Stage		
Region	As of Feb.5, 2009	As of Nov.7, 2008 (Previous announcement)	Remarks
U.S.	P2	P2	Generic name:
Japan	P2	P2	Rivoglitazone

• **DE-105** (Persistent corneal epithelial defects)

Region	Development Stage		
	As of Feb.5, 2009	As of Nov.7, 2008 (Previous announcement)	Remarks
Japan U.S.	Preparing P2	P1	Combination of peptides

Status of Major Pipeline - Retinal Disease -

• **DE-102** (Diabetic macular edema)

Region	Development Stage		_
	As of Feb.5, 2009	As of Nov.7, 2008 (Previous announcement)	Remarks
Japan	P1 / 2a	P1 / 2a	Steroid DDS

• **DE-109*** (Wet age related macular degeneration, diabetic macular edema)

Region	Development Stage		
	As of Feb.5, 2009	As of Nov.7, 2008 (Previous announcement)	Remarks
Japan	Preparing P1 / 2a	Preparing P1 / 2a	Generic name: Sirolimus

 Santen made a research and development collaboration and license agreement with MacuSight Inc. for the Japanese and Asian development and commercialization of sirolimus for the treatment of ocular diseases.

Status of Major Pipeline - Others -

• **DE-103** (Allergic conjunctivitis)

Region	Development Stage		
	As of Feb.5, 2009	As of Nov.7, 2008 (Previous announcement)	Remarks
Japan	Discontinued	P2	PDE4 inhibitor

• DE-108 (Bacterial conjunctivitis)

	Development Stage		
Region	As of Feb.5, 2009	As of Nov.7, 2008 (Previous announcement)	Remarks
Japan	P3	Preparing P3	higher-concentration Levofloxacin

• DE-098* (Rheumatoid arthritis)

Region	Development Stage		
	As of Feb.5, 2009	As of Nov.7, 2008 (Previous announcement)	Remarks
Japan	P1 / 2a	P1 / 2a	Anti ABO 1 antibady
Europe	P1 / 2a	P1 / 2a	Anti-APO-1 antibody

*Domestic development rights was licensed to Argenes, Inc. Domestic marketing rights and oversea development and marketing rights belong to Santen.



Forward-Looking Statements


- Information given in this announcement and accompanying documentation contains certain forward-looking statements concerning forecasts, projections and plans whose realization is subject to risk and uncertainty from a variety of sources. Actual results may differ significantly from forecasts.
- Business performance and financial condition are subject to the effects of medical regulatory changes made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.
- The process of drug research and development from discovery to final approval and sales is long, complex and uncertain. Individual compounds are subject to a multitude of uncertainties, including the termination of clinical development at various stages and the nonapproval of products after a regulatory filing has been submitted. Forecasts and projections concerning new products take into account assumptions concerning the development pipelines of other companies and any co-promotion agreements, existing or planned. The success or failure of such agreements could affect business performance and financial condition significantly.
- Business performance and financial conditions could be affected significantly by a substantial drop in sales of a major drug, either currently marketed or expected to be launched, due to termination of sales as a result of factors such as patent expiry and complications, product defects or unforeseen side effects. Santen Pharmaceutical also sells numerous products under sales and/or manufacturing license from other companies. Business performance could be affected significantly by changes in the terms and conditions of agreements and/or the non-renewal of agreements.
- Santen Pharmaceutical is reliant on specific companies for supplies of certain raw materials used in production. Business performance could be affected significantly by the suspension or termination of supplies of such raw materials if such and event were to adversely affect supply capabilities for related final products.



Reference: Market Overview of Prescription Pharmaceuticals in Japan (Ophthalmics / Anti-rheumatics)


S Trend & Competition by Category (Ophthalmics Total)

- Santen owns number one position with around 40% value share.
- Santen maintains the share level of FY07 by 38.9% in FY08 3Q YTD, and the latest monthly share achieved 39.8% in December 2008.




S Trend & Competition by Category (Glaucoma)

- Glaucoma is the largest category in ophthalmics, together with 1.9% value growth in FY08 3Q YTD.
- While Santen is currently the second largest, the monthly share in December 2008 achieved 23.6% together with the new product TAPROS launched in that month.




S Trend & Competition by Category (Cornea: Dry Eye)

- Dry eye is one of the highest potential category by ¥30 billion size with 6.3% growth in 3Q YTD.
- For Santen, it is the strongest category in competition, with over 75% share and 4.9% growth.




S Trend & Competition by Category (Anti-infection)

- Market size is around ¥25 billion. Value growth in 3Q YTD is slightly in declining trend by -2.9%.
- For Santen, it is another strongest category in competition, with 70% market share.




S Trend & Competition by Category (Anti-allergy)

- Market size is ¥25 billion. Recent value growth in 3Q YTD is +2.6%, while it tends to fluctuate depending on the heaviness of the pollen count in every spring.
- Santen maintains the strongest position while the competition with new products is getting tougher.




S Trend & Competition by Category (RA: DMARDs*)

- Market size of DMARDs, one of the most common drugs in anti-RA market, is ¥24 billion with +1.9% growth in 3Q YTD.
- Santen is the strongest with 45% value share in DMARDs category, led by the three products which all have the "recommended level A" authorized by the guideline of RA society.



S Reference: Focusing in High Potential Growth Area

Focusing our resources in area with a prospectively strong growth outlook and are looking to achieve above-average growth.



- All numbers are NHI price base

Source: Santen, market definition part estimated with IMS-JPM data 27 ©2009 IMS Japan, IMS-JPM 2005-08